Date: | November 2018 |
PMID: | |
Category: | 1 |
Authors: | William E Fisher, Zobeida Cruz-Monserrate 1, Amy L McElhany, Gregory B Lesinski 2, Phil A Hart 1, Ria Ghosh 3, George Van Buren, Douglas S Fishman 4, Jo Ann S Rinaudo 5, Jose Serrano 6, Sudhir Srivastava 5, Thomas Mace 1, Mark Topazian 7, Ziding Feng 3, Dhiraj Yadav 8, Stephen J Pandol 9, Steven J Hughes 10, Robert Y Liu 11, Emily Lu 11, Robert Orr 12, David C Whitcomb 7, Amer S Abouhamze 13, Hanno Steen 14, Zachary M Sellers 15, David M Troendle 16, Aliye Uc 17, Mark E Lowe 18, Darwin L Conwell 1; Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) |
Abstract: |
|
High-quality and well-annotated biorepositories are needed to better understand the pathophysiology and biologic mechanisms of chronic pancreatitis (CP) and its consequences. We report a methodology for the development of a robust standard operating procedure (SOP) for a biorepository based on the experience of the clinical centers within the consortium to study Chronic Pancreatitis, Diabetes and Pancreas Cancer Clinical Centers (CPDPC), supported by the National Cancer Institute and the National Institute for Diabetes and Digestive and Kidney Diseases as a unique multidisciplinary model to study CP, diabetes, and pancreatic cancer in both children and adults. Standard operating procedures from the CPDPC centers were evaluated and consolidated. The literature was reviewed for standard biorepository operating procedures that facilitated downstream molecular analysis. The existing literature on biobanking practices was harmonized with the SOPs from the clinical centers to produce a biorepository for pancreatic research. This article reports the methods and basic principles behind the creation of SOPs to develop a biorepository for the CPDPC. These will serve as a guide for investigators developing biorepositories in pancreas research. Rigorous and meticulous adherence to standardized biospecimen collection will facilitate investigations to better understand the pathophysiology and biologic mechanisms of CP, diabetes, and pancreatic cancer.
Acknowledgements:
The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute, the National Institute of Health, or the National Institute of Diabetes and Digestive and Kidney Diseases.
The Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) Research Consortia is supported and funded by grants from the National Cancer Institute and the National Institute of Diabetes and Digestive and Kidney Diseases under the following award numbers:
Project Number: | Awardee Organization |
U01DK108326 | Baylor College of Medicine |
U01DK108314 | Cedars-Sinai Medical Center |
U01DK108332 | Indiana University |
U01DK108323 | Kaiser Foundation Research Institute |
U01DK108288 | Mayo Clinic |
U01DK108327 | Ohio State University |
U01DK108300 | Stanford University |
U01DK108320 | University of Florida |
U01DK108306 | University of Pittsburgh |
U01DK108328 | University of Texas MD Anderson Cancer Center |
Comments